SecBot SecBot
8-K ·Filed May 7, 2026

IRWD

IRONWOOD PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizondays Processed6mo ago SEC0001104659-26-056656
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The massive beat confirms strong LINZESS pricing recovery and demand growth. While guidance was maintained, the Q1 trajectory suggests potential upward revision later. Watch for the June convertible note maturity, strong operating cash flow should ease refinancing risk. The May 24 PDUFA for pediatric LINZESS could provide further upside.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.17
T+0 close · May 7, 2026 · via day close
Latest settled
+6.00%
T+60 · $4.42
Vs SPY
+2.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $4.17entry
  2. T+1 · 6mo ago +1.20%α +0.37% · $4.22
  3. T+5 · 6mo ago −11.75%α −13.26% · $3.68
  4. T+20 · 6mo ago −22.30%α −25.44% · $3.24
  5. T+60 · 4mo ago +6.00%α +2.16% · $4.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (+243%) and revenue of $106.5M, driven by a 97% surge in LINZESS U.S. net sales to $272.5M due to improved net pricing. Full-year 2026 guidance was maintained, with LINZESS net sales expected at $1.125-$1.175B and adjusted EBITDA >$300M. The strong cash generation positions the company for its June convertible note maturity.

Key Financial Metrics

EPS
$0.24
est $0.07 · +242.9%
Revenue
$106.5M
+159.0% YoY
Rating
strong beat
Guidance
$450M-$475M
maintained

Key Facts

  • GAAP diluted EPS $0.24 vs consensus $0.07 (beat by 243%)
  • Total revenue $106.5M, up 159% YoY from $41.1M
  • LINZESS U.S. net sales $272.5M, up 97% YoY
  • Collaboration revenue $104.2M, up 169% YoY
  • GAAP net income $40.8M vs loss of $37.4M in Q1 2025
  • Adjusted EBITDA $76.7M vs ($4.7M) in Q1 2025
  • Full-year 2026 guidance maintained: LINZESS net sales $1.125-$1.175B, total revenue $450-$475M, adjusted EBITDA >$300M
  • Cash and cash equivalents $220.5M, with $199.9M convertible notes maturing in June 2026
  • sNDA for LINZESS in functional constipation (ages 2-5) granted priority review with PDUFA date May 24, 2026

Financial Impact

EPS beat of $0.17 vs consensus, revenue beat of ~$14M vs consensus, representing a 159% YoY revenue increase and swing to profitability

revenueepscashFlowdebt

Risk Factors

  • Full-year guidance maintained despite strong Q1, implying potential for lower revenue in later quarters
  • Convertible note maturity of ~$200M in June 2026 requires cash or refinancing
  • Apraglutide Phase 3 trial initiations carry execution and regulatory risk
  • LINZESS faces potential generic competition and pricing pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-056656
Document: tm267094d1_8k.htm0001104659-26-056656
Document: 0001104659-26-056656-index-headers.html0001104659-26-056656
Document: 0001104659-26-056656-index.html0001104659-26-056656
Document: 0001104659-26-056656.txt0001104659-26-056656
8-K Data (Synthetic)0001104659-26-056656

Track record

13 reports on IRWD

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+5 after the Nov 5, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 Now $4.85 −0.51% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 Now $4.85 +0.21% settles Dec 15
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $4.03 Now $4.85 +20.35% settles Dec 4
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 Now $4.85 +34.35% settles Nov 25
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 Now $4.85 +38.57% ▲ +38.57% +39.73% vs SPY
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $4.26 to $4.29 Now $4.85 +13.85% ▲ +0.70% +0.10% vs SPY
  9. May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 Now $4.85 +31.79% ▼ −1.36% −0.75% vs SPY
  10. May 7, 202627w ago 8-K Bullish 7/10 Viewing Entry $4.17 to $3.24 Now $4.85 +16.31% ▼ −22.30% −25.44% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026